The weeks Case in Point is about plea deals in specific “C” pleas — which tend to favor mostly corporations. Drug maker Aegerion arranged one such "C" plea after being charged with misconduct for the drug Juxtapid,which was used to treat people who suffer from a combination of a rare genetic disease and tall cholesterol. The cost of the drug skyrocketed to nearly $300000 a year for patients. But the company went even further and committed "egregious misconduct" in its tactics targeting patients. Andrew Cohen, senior editor at The Marshall Project and author of Case in Point, or describes how the "C" plea deal was ultimately rejected by a federal judge who was not going to allow the drug company to rep off easy.
You can read the full article by Andrew Cohen at The Marshall Project. This segment is hosted by Todd Zwillich
Source: thetakeaway.org